Company News: Ares Genetics, a Curetis Group Company, Joins NVIDIA Inception and AWS Activate Programs

— Ares Genetics selected for NVIDIA and AWS programs to accelerate commercialization of its AI-powered Universal Pathogenome Assay – ARESupa

— NVIDIA Inception program accelerates start-ups that revolutionize industries with advancements in AI

Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that its fully-owned subsidiary Ares Genetics has joined the NVIDIA Inception program as a community member.

The Inception program is designed to nurture start-ups revolutionizing industries with advancements in AI and data sciences. This virtual accelerator offers go-to-market support, expertise, and technology for program members through deep learning training, exclusive Inception events, and GPU discounts.

The Company further announced that it has been selected for the AWS Activate program, under which Amazon Web Services (AWS) provides portfolio start-ups with the resources they need to quickly start and scale their digital businesses on AWS. Under the AWS Activate program, Ares Genetics will receive cloud computing credits, training, and support to accelerate development and commercialization of its AI-powered ARESupa.

NVIDIA is partnering with AWS to provide leading-edge infrastructure to start-ups so they can innovate and grow. Members of either company’s start-up program — NVIDIA Inception or AWS Activate — are eligible to receive benefits provided by the other.

Ares Genetics is a digital diagnostics company utilizing AI-powered molecular diagnostics to advance the field of infectious disease testing. The Company has recently launched the ARESupa – Universal Pathogenome Assay, an award-winning tool for personalized antibiotic susceptibility prediction combining next-generation sequencing with AI. ARESupa is based on whole-genome sequencing of bacterial strains isolated from clinical specimens, combined with data analysis and interpretation powered by ARESdb, Ares Genetics’ unique, proprietary reference database on genetic antimicrobial resistance markers. ARESdb covers genomes of about 40,000 bacterial strains and associated susceptibility data for more than 100 different antibiotics. Currently under development is an ARESupa laboratory-developed test on native patient samples for human diagnostic use in indications in which current culture-based diagnostic practice is inherently challenging. Additionally, the Company has teamed up with Sandoz and launched a pharma partnering program in December 2018 to support drug development and life cycle management via a digital anti-infectives platform combining established microbiology laboratory methods with advanced bioinformatics and AI methods.

“We are proud that the further development and commercialization of our AI-powered solutions for infectious disease diagnostics and therapeutics will be supported by two of the world’s leading companies in AI, data-driven solutions, and cloud computing,” commented Dr. Andreas Posch, Managing Director and CEO of Ares Genetics. “Already today, we support various leading customers in the healthcare and pharma industry with our ARESupa test and are currently working on globally scaling our business via our cloud-based interpretation platform.”